Osteoporosis Therapeutics Market
Osteoporosis Therapeutics Market Analysis by Drug Class (Bisphosphonates, Selective Estrogen Inhibitor Modulators (SERM), Parathyroid Hormone Therapies), by Route of Administration (Oral, Injectable), by Region - Global Forecast 2022 to 2026
Analysis of Osteoporosis Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Market Outlook of Osteoporosis Therapeutics
The global osteoporosis therapeutics market stands at a valuation of US$ 12.7 Bn currently, and is predicted to reach US$ 14.2 Bn by the end of 2026.
Consumption of osteoporosis therapeutic drugs is anticipated to increase at a CAGR of 2.9% from 2022 to 2026.
| Report Attributes | Details |
|---|---|
| Osteoporosis Therapeutics Market Size (2022) | US$ 12.7 Bn |
| Projected Year Value (2026F) | US$ 14.2 Bn |
| Global Market Growth Rate (2022 to 2026) | 2.9% CAGR |
| United States Market Share (2022) | 41% |
| Key Companies Profiled | Allergan Plc.; Amgen Inc.; Chugai Pharmaceutical; Daiichi Sankyo Co. Ltd.; Egalet Corporation; Eisai Co. Ltd.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd. |
Demand for osteoporosis therapeutics in China is expected to progress at a higher than global average CAGR of 5.4% through 2026. Poor lifestyle choices and rising aging population have majorly influenced demand for osteoporosis treatment on a global scale.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Osteoporosis Therapeutics Demand Analysis (2017 to 2021) in Comparison to Market Growth Forecasts (2022 to 2026)
Incidence of osteoporosis has witnessed an exponential rise over the past few years and this trend is expected to be prevalent over the coming years as well. Osteoporosis is still one of the major diseases that go undiagnosed and untreated due to a lack of awareness about the condition.
Increasing geriatric population, rising awareness for osteoporosis, increasing availability of diagnostic procedures, growing sedentary lifestyle, and rapid development of novel treatments are major factors that guide the osteoporosis therapeutics market growth through 2026.
Longer time taken by regulatory bodies for approval of new osteoporosis drugs and side effects associated with prolonged use of the same are expected to have a restraining effect on the global osteoporosis therapeutics market potential.
Sales of osteoporosis drugs are projected to rise at a sluggish CAGR of 2.9% from 2022 to 2026.
What Will Favor Demand for Osteoporosis Drugs Going Ahead?
“Surging Aging Population to Boost Consumption of Osteoporosis Therapeutic Drugs”
The world is witnessing a significant rise in its aging population and this has shaped the healthcare industry with new opportunities. Osteoporosis is very common in the geriatric population and hence as the aging population increases, it drives a caseload of osteoporosis as well.
China and the United States are two prominent markets where the geriatric population is increasing and hence will be rewarding markets for osteoporosis drug vendors.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
How is Osteoporosis Therapeutics Market Growth Being Hindered?
“Long Approval Times by Regulatory Authorities to Dent Osteoporosis Drug Sales”
All drugs have to undergo an approval procedure by respective regulatory authorities of their regions in order to be commercialized and available for patients and healthcare professionals.
The time taken for approval by these authorities for osteoporosis drugs is long and hence delays entry into the market and slows down osteoporosis therapeutics market potential.
“Lack of Awareness & Proper Diagnosis to Hinder Market Expansion”
General awareness about osteoporosis is very low compared to other prevalent diseases and this has hampered osteoporosis therapeutics market potential in the past and is expected to follow a similar trend over the forecast period as well.
Furthermore, the lack of diagnostic equipment for osteoporosis is also expected to constrain osteoporosis therapeutics market growth throughout the forecast period.
Which Regional Markets Should Osteoporosis Therapeutic Drug Suppliers Focus On?
“North America Expected to Account for Highest Osteoporosis Therapeutics Demand”
The North America osteoporosis therapeutics market is anticipated to have a bright outlook over the coming years and will hold a dominant market share in the global landscape.
Increasing sedentary lifestyles, rising instances of osteoporosis, the presence of developed healthcare infrastructure, and high healthcare spending potential are expected to be major factors influencing shipments of osteoporosis drugs through 2026.
The Europe osteoporosis therapeutics market is expected to hold a significant market share in the global landscape throughout the forecast period. Increasing spending on research and development activities are expected to prominently influence osteoporosis therapeutics market potential in this region.
South Asia and East Asia are predicted to provide lucrative opportunities for osteoporosis therapeutics market players. Rising awareness of osteoporosis, increasing healthcare expenditure, and the growing aging population in the aforementioned regions are expected to majorly influence osteoporosis therapeutics market growth.
Malaysia, India, and China are anticipated to be rewarding markets for osteoporosis drug suppliers.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Country-wise Insights
Why Should Osteoporosis Drug Manufacturers Focus on the U.S.?
“Increasing Incidence of Osteoporosis & High Healthcare Spending Provide Attractive Opportunities”
The U.S. is a highly lucrative market for healthcare products and technologies due to the presence of developed healthcare infrastructure in the nation. The nation has witnessed an increase in the aging population and this is a prominent factor that influences osteoporosis treatment demand in the U.S.
The U.S. accounts for a substantial market share of 41% in the global osteoporosis therapeutics industry landscape.
Will Osteoporosis Drug Suppliers Benefit in China?
“Surging Geriatric Population to Majorly Boost Consumption of Osteoporosis Drugs”
China has witnessed a noteworthy increase in the geriatric population and this will majorly guide osteoporosis drug shipments throughout the forecast period. Increasing healthcare expenditure and rising awareness about osteoporosis are expected to be other trends sculpting osteoporosis therapeutics market growth.
Osteoporosis therapeutic drug consumption is projected to rise at a CAGR of 5.4% from 2022 to 2026 in China.
Category-wise Insights
Which Route of Administration of Osteoporosis Drug Will Hold Major Market Share?
“Oral Route of Administration to Remain Most Popular”
Of the two major routes of administration, the oral segment is anticipated to account for a major market share in the global osteoporosis therapeutics landscape. This can be attributed to the high availability of oral osteoporosis drugs across the world.
However, the injectables segment is projected to see fast growth in sales over the next few years as demand for rapid action drugs increases on a global scale.
How Did the Osteoporosis Therapeutics Market Perform in 2020?
The world witnessed a pandemic of epic proportions in 2020 with the unprecedented outbreak of coronavirus infections and this led to major changes in the world economy. To contain the spread of coronavirus infections, multiple nations implemented total lockdowns and this led to the toppling of various markets.
Change of focus in the healthcare industry due to the pandemic led to a downfall in the osteoporosis therapeutics market growth as well. Lack of healthcare resources and lack of attention to the disease were two major factors slowing down the osteoporosis therapeutics market in 2020. Lack of diagnosis and closure of multiple sales channels also had a negative impact on the osteoporosis therapeutics market.
Osteoporosis drug sales are projected to see slow growth in the post-pandemic era and are anticipated to pick up pace as awareness of osteoporosis increases across the world. Increased focus on preventive healthcare in the post-pandemic world will also drive demand for osteoporosis prevention therapeutics.
Competitive Landscape
Osteoporosis drug manufacturers are increasing their investments in the research and development of novel drugs to fast-track new launches. Osteoporosis treatment injections are gaining popularity and market players are trying to launch these to advance their revenue potential in the global market.
- In October 2021, Entera Bio, a leading biotechnology company, posted crucial data for its oral osteoporosis drug formulation trial that is in its mid-stage. The company moved ahead to phase 3 registration of this study.
Key Segments Covered in Osteoporosis Therapeutics Industry Research
-
By Drug Class :
- Bisphosphonates
- Selective Estrogen Inhibitor Modulators (SERM)
- Parathyroid Hormone Therapies
- Calcitonin
- Rank Ligand Inhibitors
-
By Route of Administration :
- Oral Osteoporosis Therapeutics
- Injectable Osteoporosis Therapeutics
- Other Routes of Administration
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Key Success Factors
- 5. Market Background
- 6. Global Market Volume (Units) Analysis 2017 to 2021 and Forecast, 2022 to 2026
- 7. Global Market - Pricing Analysis
- 8. Global Market Value Analysis 2017 to 2021 and Forecast, 2022 to 2026
- 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2026, by Drug Class
- 9.1. Bisphosphonates
- 9.2. Selective Estrogen Inhibitor Modulators (SERM)
- 9.3. Parathyroid Hormone Therapies
- 9.4. Calcitonin
- 9.5. Rank Ligand Inhibitors
- 10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2026, by Route of Administration
- 10.1. Oral
- 10.2. Injectables
- 10.3. Other Routes of Administration
- 11. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2026, by Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Europe
- 11.4. East Asia
- 11.5. South Asia
- 11.6. Oceania
- 11.7. Middle East and Africa (MEA)
- 12. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2026
- 13. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2026
- 14. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2026
- 15. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2026
- 16. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2026
- 17. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2026
- 18. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2026
- 19. Key and Emerging Countries Market Analysis 2017 to 2021 and Forecast 2022 to 2026
- 20. Market Structure Analysis
- 21. Competition Analysis
- 21.1. Allergan Plc.
- 21.2. Amgen Inc.
- 21.3. Chugai Pharmaceutical
- 21.4. Daiichi Sankyo Co. Ltd.
- 21.5. Egalet Corporation
- 21.6. Eisai Co. Ltd.
- 21.7. Eli Lilly and Company
- 21.8. F. Hoffmann-La Roche Ltd.
- 22. Assumptions and Acronyms Used
- 23. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Volume (‘000 Units) Analysis and Opportunity Assessment 2017 to 2026, By Drug Class
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Drug Class
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Route of Administration
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Region
Table 05: North America Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2026, By Country
Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Drug Class
Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Route of Administration
Table 08: Latin America Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2026, By Country
Table 09: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Drug Class
Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Route of Administration
Table 11: Europe Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2026, By Country
Table 12: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Drug Class
Table 13: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Route of Administration
Table 14: South Asia Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2026, By Country
Table 15: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Drug Class
Table 16: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Route of Administration
Table 17: East Asia Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2026, By Country
Table 18: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Drug Class
Table 19: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Route of Administration
Table 20: Oceania Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2026, By Country
Table 21: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Drug Class
Table 22: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Route of Administration
Table 23: Middle East and Africa Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2026, By Country
Table 24: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Drug Class
Table 25: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2026, By Route of Administration
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Volume (in 000' Units) Analysis, 2017 to 2021
Figure 02: Global Market Volume Forecast (in 000' Units), 2022 to 2026
Figure 03: Pricing Analysis (US$) Per Product, By Region, 2021
Figure 04: Pricing Analysis (US$) Per Product, By Region, 2021
Figure 05: Global Market Value Analysis (US$ Mn), 2017 to 2021
Figure 06: Global Market Value Forecast (US$ Mn), 2022 to 2026
Figure 07: Global Market Absolute $ Opportunity, 2022 to 2026
Figure 08: Global Market Share Analysis (%), By Drug Class, 2022 to 2026
Figure 09: Global Market Y-o-Y Analysis (%), By Drug Class, 2022 to 2026
Figure 10: Global Market Attractiveness Analysis by Drug Class, 2022 to 2026
Figure 11: Global Market Share Analysis (%), By Route of Administration, 2022 to 2026
Figure 12: Global Market Y-o-Y Analysis (%), By Route of Administration, 2022 to 2026
Figure 13: Global Market Attractiveness Analysis by Route of Administration, 2022 to 2026
Figure 14: Global Market Share Analysis (%), By Region, 2022 to 2026
Figure 15: Global Market Y-o-Y Analysis (%), By Region, 2022 to 2026
Figure 16: Global Market Attractiveness Analysis by Region, 2022 to 2026
Figure 17: North America Market Value Share, By Drug Class, 2022 (E)
Figure 18: North America Market Value Share, By Route of Administration, 2022 (E)
Figure 19: North America Market Value Share, By Country, 2022 (E)
Figure 20: North America Market Value Analysis (US$ Mn), 2017 to 2021
Figure 21: North America Market Value Forecast (US$ Mn), 2022 to 2026
Figure 22: North America Market Attractiveness Analysis by Drug Class, 2022 to 2026
Figure 23: North America Market Attractiveness Analysis by Route of Administration, 2022 to 2026
Figure 24: North America Market Attractiveness Analysis by Country, 2022 to 2026
Figure 25: Latin America Market Value Share, By Drug Class, 2022 (E)
Figure 26: Latin America Market Value Share, By Route of Administration, 2022 (E)
Figure 27: Latin America Market Value Share, By Country, 2022 (E)
Figure 28: Latin America Market Value Analysis (US$ Mn), 2017 to 2021
Figure 29: Latin America Market Value Forecast (US$ Mn), 2022 to 2026
Figure 30: Latin America Market Attractiveness Analysis by Drug Class, 2022 to 2026
Figure 31: Latin America Market Attractiveness Analysis by Route of Administration, 2022 to 2026
Figure 32: Latin America Market Attractiveness Analysis by Country, 2022 to 2026
Figure 33: Europe Market Value Share, By Drug Class, 2022 (E)
Figure 34: Europe Market Value Share, By Route of Administration, 2022 (E)
Figure 35: Europe Market Value Share, By Country, 2022 (E)
Figure 36: Europe Market Value Analysis (US$ Mn), 2017 to 2021
Figure 37: Europe Market Value Forecast (US$ Mn), 2022 to 2026
Figure 38: Europe Market Attractiveness Analysis by Drug Class, 2022 to 2026
Figure 39: Europe Market Attractiveness Analysis by Route of Administration, 2022 to 2026
Figure 40: Europe Market Attractiveness Analysis by Country, 2022 to 2026
Figure 41: South Asia Market Value Share, By Drug Class, 2022 (E)
Figure 42: South Asia Market Value Share, By Route of Administration, 2022 (E)
Figure 43: South Asia Market Value Share, By Country, 2022 (E)
Figure 44: South Asia Market Value Analysis (US$ Mn), 2017 to 2021
Figure 45: South Asia Market Value Forecast (US$ Mn), 2022 to 2026
Figure 46: South Asia Market Attractiveness Analysis by Drug Class, 2022 to 2026
Figure 47: South Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2026
Figure 48: South Asia Market Attractiveness Analysis by Country, 2022 to 2026
Figure 49: East Asia Market Value Share, By Drug Class, 2022 (E)
Figure 50: East Asia Market Value Share, By Route of Administration, 2022 (E)
Figure 51: East Asia Market Value Share, By Country, 2022 (E)
Figure 52: East Asia Market Value Analysis (US$ Mn), 2017 to 2021
Figure 53: East Asia Market Value Forecast (US$ Mn), 2022 to 2026
Figure 54: East Asia Market Attractiveness Analysis by Drug Class, 2022 to 2026
Figure 55: East Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2026
Figure 56: East Asia Market Attractiveness Analysis by Country, 2022 to 2026
Figure 57: Oceania Market Value Share, By Drug Class, 2022 (E)
Figure 58: Oceania Market Value Share, By Route of Administration, 2022 (E)
Figure 59: Oceania Market Value Share, By Country, 2022 (E)
Figure 60: Oceania Market Value Analysis (US$ Mn), 2017 to 2021
Figure 61: Oceania Market Value Forecast (US$ Mn), 2022 to 2026
Figure 62: Oceania Market Attractiveness Analysis by Drug Class, 2022 to 2026
Figure 63: Oceania Market Attractiveness Analysis by Route of Administration, 2022 to 2026
Figure 64: Oceania Market Attractiveness Analysis by Country, 2022 to 2026
Figure 65: Middle East and Africa Market Value Share, By Drug Class, 2022 (E)
Figure 66: Middle East and Africa Market Value Share, By Route of Administration, 2022 (E)
Figure 67: Middle East and Africa Market Value Share, By Country, 2022 (E)
Figure 68: Middle East and Africa Market Value Analysis (US$ Mn), 2017 to 2021
Figure 69: Middle East and Africa Market Value Forecast (US$ Mn), 2022 to 2026
Figure 70: Middle East and Africa Market Attractiveness Analysis by Drug Class, 2022 to 2026
Figure 71: Middle East and Africa Market Attractiveness Analysis by Route of Administration, 2022 to 2026
Figure 72: Middle East and Africa Market Attractiveness Analysis by Country, 2022 to 2026
Figure 73: U. S. Market Value Analysis (US$ Mn), 2022 & 2026
Figure 74: U. S. Market Value Share, By Drug Class, 2022 (E)
Figure 75: U. S. Market Value Share, By Route of Administration, 2022 (E)
Figure 76: Canada Market Value Analysis (US$ Mn), 2022 & 2026
Figure 77: Canada Market Value Share, By Drug Class, 2022 (E)
Figure 78: Canada Market Value Share, By Route of Administration, 2022 (E)
Figure 79: Mexico Market Value Analysis (US$ Mn), 2022 & 2026
Figure 80: Mexico Market Value Share, By Drug Class, 2022 (E)
Figure 81: Mexico Market Value Share, By Route of Administration, 2022 (E)
Figure 82: Brazil Market Value Analysis (US$ Mn), 2022 & 2026
Figure 83: Brazil Market Value Share, By Drug Class, 2022 (E)
Figure 84: Brazil Market Value Share, By Route of Administration, 2022 (E)
Figure 85: U. K. Market Value Analysis (US$ Mn), 2022 & 2026
Figure 86: U. K. Market Value Share, By Drug Class, 2022 (E)
Figure 87: U. K. Market Value Share, By Route of Administration, 2022 (E)
Figure 88: Germany Market Value Analysis (US$ Mn), 2022 & 2026
Figure 89: Germany Market Value Share, By Drug Class, 2022 (E)
Figure 90: Germany Market Value Share, By Route of Administration, 2022 (E)
Figure 91: France Market Value Analysis (US$ Mn), 2022 & 2026
Figure 92: France Market Value Share, By Drug Class, 2022 (E)
Figure 93: France Market Value Share, By Route of Administration, 2022 (E)
Figure 94: Italy Market Value Analysis (US$ Mn), 2022 & 2026
Figure 95: Italy Market Value Share, By Drug Class, 2022 (E)
Figure 96: Italy Market Value Share, By Route of Administration, 2022 (E)
Figure 97: Spain Market Value Analysis (US$ Mn), 2022 & 2026
Figure 98: Spain Market Value Share, By Drug Class, 2022 (E)
Figure 99: Spain Market Value Share, By Route of Administration, 2022 (E)
Figure 100: Russia Market Value Analysis (US$ Mn), 2022 & 2026
Figure 101: Russia Market Value Share, By Drug Class, 2022 (E)
Figure 102: Russia Market Value Share, By Route of Administration, 2022 (E)
Figure 103: China Market Value Analysis (US$ Mn), 2022 & 2026
Figure 104: China Market Value Share, By Drug Class, 2022 (E)
Figure 105: China Market Value Share, By Route of Administration, 2022 (E)
Figure 106: Japan Market Value Analysis (US$ Mn), 2022 & 2026
Figure 107: Japan Market Value Share, By Drug Class, 2022 (E)
Figure 108: Japan Market Value Share, By Route of Administration, 2022 (E)
Figure 109: South Korea Market Value Analysis (US$ Mn), 2022 & 2026
Figure 110: South Korea Market Value Share, By Drug Class, 2022 (E)
Figure 111: South Korea Market Value Share, By Route of Administration, 2022 (E)
Figure 112: India Market Value Analysis (US$ Mn), 2022 & 2026
Figure 113: India Market Value Share, By Drug Class, 2022 (E)
Figure 114: India Market Value Share, By Route of Administration, 2022 (E)
Figure 115: ASEAN Market Value Analysis (US$ Mn), 2022 & 2026
Figure 116: ASEAN Market Value Share, By Drug Class, 2022 (E)
Figure 117: ASEAN Market Value Share, By Route of Administration, 2022 (E)
Figure 118: Australia Market Value Analysis (US$ Mn), 2022 & 2026
Figure 119: Australia Market Value Share, By Drug Class, 2022 (E)
Figure 120: Australia Market Value Share, By Route of Administration, 2022 (E)
Figure 121: New Zealand Market Value Analysis (US$ Mn), 2022 & 2026
Figure 122: New Zealand Market Value Share, By Drug Class, 2022 (E)
Figure 123: New Zealand Market Value Share, By Route of Administration, 2022 (E)
Figure 124: GCC Countries Market Value Analysis (US$ Mn), 2022 & 2026
Figure 125: GCC Countries Market Value Share, By Drug Class, 2022 (E)
Figure 126: GCC Countries Market Value Share, By Route of Administration, 2022 (E)
Figure 127: Turkey Market Value Analysis (US$ Mn), 2022 & 2026
Figure 128: Turkey Market Value Share, By Drug Class, 2022 (E)
Figure 129: Turkey Market Value Share, By Route of Administration, 2022 (E)
Figure 130: South Africa Market Value Analysis (US$ Mn), 2022 & 2026
Figure 131: South Africa Market Value Share, By Drug Class, 2022 (E)
Figure 132: South Africa Market Value Share, By Route of Administration, 2022 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the osteoporosis therapeutics market value at present?
The global osteoporosis therapeutics market is valued at US$ 12.7 Bn at present.
How big will the osteoporosis therapeutics market be by 2026?
The global market for osteoporosis therapeutics is slated to reach a valuation of US$ 14.2 Bn by the end of 2026.
How will demand for osteoporosis therapeutic drugs rise over the forecast period?
Consumption of osteoporosis therapeutic drugs is projected to expand at a sluggish CAGR 2.9% from 2022 to 2026.
Who are the key osteoporosis therapeutics market players mentioned in this research?
Key osteoporosis therapeutic drug manufacturers are Allergan Plc., Amgen Inc., Chugai Pharmaceutical, Daiichi Sankyo Co. Ltd., Egalet Corporation, and Eisai Co. Ltd.
What market share is held by the U.S?
The U.S. currently accounts for 41% of the global osteoporosis therapeutics market share.
At what rate will the China osteoporosis therapeutics market expand?
The China osteoporosis therapeutics market is anticipated to rise at a CAGR of 5.4% from 2022 to 2026.
Osteoporosis Therapeutics Market